Table 2 Distribution of BRCA2 cases according to the TNM and receptor status
From: Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia
| Â | Primary tumour size | ||
|---|---|---|---|
BRCA2mutation | T1-2 | T3-4 | Total |
Negative | 421 91% | 43 9% | 464 |
Positive | 41 93% | 3 7% | 44 |
Total | 462 91% | 46 9% | 508 |
| Â | Lymph node metastasis | ||
BRCA2 mutation | Negative | Positive | Total |
Negative | 263 57% | 201 43% | 464 |
Positive | 24 55% | 20 45% | 44 |
Total | 287 56% | 221 44% | 508 |
| Â | Distant metastasis | ||
BRCA2 mutation | Absent | Present | Total |
Negative | 434 94% | 30 6% | 464 |
Positive | 41 93% | 3 7% | 44 |
Total | 475 94% | 33 6% | 508 |
| Â | Estrogen receptor | ||
BRCA2 mutation | Negative | Positive | Total |
Negative | 91 26% | 257 74% | 348 |
Positive | 5 29% | 12 71% | 17 |
Total | 96 26% | 269 74% | 365 |
| Â | Progesterone receptor | ||
BRCA2 mutation | Negative | Positive | Total |
Negative | 150 44% | 189 56% | 339 |
Positive | 6 46% | 7 54% | 13 |
Total | 156 44% | 196 56% | 352 |